Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 1/20 | 0.52 |
| ▸ | GSR | P00390 | 1/20 | 0.45 |
| ▸ | GNPAT | O15228 | 1/20 | 0.44 |
| ▸ | CPB2 | Q96IY4 | 7/20 | 0.43 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.42 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.41 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.41 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.41 |
| ▸ | ECE1 | P42892 | 1/20 | 0.40 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.40 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30731559 | 0.99 | FOLH1 (0.51) | FOLH1GSRGNPATCPB2SLC15A2 | |
| SCHEMBL30731558 | 0.96 | FOLH1 (0.50) | FOLH1GSRGNPATCPB2SLC15A2 | |
| SCHEMBL29663724 | 0.96 | FOLH1 (0.50) | FOLH1GSRGNPATCPB2SLC15A2 | |
| SCHEMBL14959945 | 0.96 | FOLH1 (0.53) | FOLH1GSRGNPATCPB2SLC15A2 | |
| SCHEMBL5997604 | 0.96 | FOLH1 (0.53) | FOLH1GSRGNPATCPB2SLC15A2 | |
| SCHEMBL29376049 | 0.96 | FOLH1 (0.53) | FOLH1GSRGNPATCPB2SLC15A2 | |
| SCHEMBL10700763 | 0.96 | FOLH1 (0.53) | FOLH1GSRGNPATCPB2SLC15A2 | |
| SCHEMBL11765786 | 0.96 | FOLH1 (0.53) | FOLH1GSRGNPATCPB2SLC15A2 | |
| SCHEMBL30640885 | 0.94 | FOLH1 (0.54) | FOLH1GSRGNPATCPB2SLC15A2 | |
| SCHEMBL30207804 | 0.93 | FOLH1 (0.52) | FOLH1GSRGNPATCPB2SLC15A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240150404-A1 | BICYCLIC PEPTIDYL INHIBITOR OF TUMOR NECROSIS FACTOR-ALPHA | OHIO STATE INNOVATION FOUNDATION | 2024-05-09 | — | — | US | disclosed |
| US-11859019-B2 | Bicyclic peptidyl inhibitor of tumor necrosis factor-alpha | OHIO STATE INNOVATION FOUNDATION (US) | 2024-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11859019-B2 | Bicyclic peptidyl inhibitor of tumor necrosis factor-alpha | NFKBIA, TNFRSF1A, NFATC1 | FOLH1 1665/4885GSR 4161/4885GNPAT 3895/4885 |
| US-20240150404-A1 | BICYCLIC PEPTIDYL INHIBITOR OF TUMOR NECROSIS FACTOR-ALPHA | NFKBIA, TNFRSF1A, NFATC1 | FOLH1 1665/4885GSR 4161/4885GNPAT 3895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.